StockNews.AI
TLX
StockNews.AI
134 days

Telix Appoints Paul Schaffer as Chief Technology Officer

1. Dr. Paul Schaffer appointed as CTO of Telix Pharmaceuticals. 2. Schaffer brings extensive experience from ARTMS and TRIUMF. 3. Telix aims to innovate in radiopharmaceutical technology. 4. Schaffer will enhance Telix's R&D capabilities using various scientific fields. 5. Company's focus on oncology and rare diseases continues to grow.

9m saved
Insight
Article

FAQ

Why Bullish?

The appointment of a seasoned CTO indicates strategic growth potential and innovation, likely boosting market confidence in TLX.

How important is it?

The leadership change reflects Telix’s commitment to innovation, likely attracting investor interest and impacting stock performance positively.

Why Long Term?

As Schaffer drives R&D, innovations could lead to future product approvals, enhancing TLX's market position.

Related Companies

ARTMSTRIUMF
April 07, 2025 06:30 ET  | Source: Telix Pharmaceuticals Limited MELBOURNE, Australia and INDIANAPOLIS, April 07, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that is has appointed Dr. Paul Schaffer to the newly created role of Chief Technology Officer (CTO), effective today. Dr. Schaffer has been CTO at ARTMS Inc. (ARTMS) (acquired by Telix in 2024) for the past seven years, as well as Director, Life Science at TRIUMF, Canada’s particle accelerator research centre, since 2012. Based in Vancouver, Canada, Dr. Schaffer is widely recognized for his role in the buildout and transformation of the TRIUMF Life Sciences program, which included design and construction of a major multi-cyclotron radiochemistry facility and the development of the ARTMS QUANTM Irradiation System® (QIS®) for large-scale isotope production, which was commercialized and later acquired by Telix. As Telix CTO, Dr. Schaffer will be responsible for harnessing the power of technology to advance Telix’s capabilities in radiopharmaceutical research, development, and clinical applications. Dr. Schaffer will cover areas including chemistry, physics, artificial intelligence (AI), dosimetry, and data analytics, complementing the work of Telix’s Chief Scientist, Dr. Michael Wheatcroft, and his team in driving cutting-edge research and development (R&D). Dr. Schaffer said, “I’m excited to be taking on this role at such a pivotal time for Telix, as the Company advances rapidly toward its mission of transforming patient care. Telix has a bold commitment to innovation, and I’m thrilled to collaborate with this talented team to help drive R&D for the technologies behind the next generation of radiotherapeutics.” Dr. Christian Behrenbruch, Telix Managing Director and Group Chief Executive Office, said, “Paul has an impressive track record of driving innovation in life sciences technology, including his groundbreaking work in large-scale isotope production. I have first-hand experience of Paul’s impressive intellect, ideas and passion through his work at TRIUMF and with ARTMS, so it is a great pleasure to have him join the broader Telix team as we continue to lead radiopharmaceutical innovation.” About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. Telix Investor Relations Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: kyahn.williamson@telixpharma.com Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2025 Telix Pharmaceuticals Limited. Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country.

Related News